Monday, March 19, 2012
Tribute Pharmaceuticals, a subsidiary of Stellar Pharmaceuticals Inc. has received the approval from Health Canada for Cambia (diclofenac potassium for oral solution) for the acute treatment of migraine attacks with or without aura in adults. Cambia is expected to be launched in Canada in the second half of 2012.
Cambia, a novel, water-soluble, buffered diclofenac potassium powder engineered using Dynamic Buffering Technology, a patented absorption-enhancing technology developed by a Swiss drug delivery and drug development company, APR Applied Pharma Research SA (APR), was specifically developed to address a widespread unmet need among patients by offering fast and effective relief of migraine pain.
Tribute, obtained the exclusive Canadian license to Cambia in November 2010 from New Jersey based Nautilus Neurosciences, Inc., a neurology-focused specialty pharmaceutical company. Tribute filed an application for approval for Cambia with Health Canada in March 2011, prior to Tribute being acquired by Stellar in December 2011.
“Health is the greatest gift, contentment the greatest wealth, faithfulness the best relationship.” Buddha[/color][/i]